Recent discovery and development of inhibitors targeting coronaviruses

doi:10.1016/j.drudis.2020.01.015

Drug Discovery Today

Volume 25, Issue 4, April 2020, Pages 668-688

https://doi.org/10.1016/j.drudis.2020.01.015 Get rights and content

Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded RNA genome. Currently, six human CoVs have been reported including human coronavirus 229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS) coronavirus (MERS-CoV). They cause moderate to severe respiratory and intestinal infections in humans. In this review, we focus on recent advances in the research and development of small-molecule anti-human coronavirus therapies targeting different stages of the CoV life cycle.

Thanigaimalai Pillaiyar received his doctoral degree in medicinal chemistry in 2011 under the supervision of Prof. Dr Sang-Hun Jung at Chungnam National University, South Korea. In 2011, he won a вЂ

Drug Discovery Today

ReviewKeynoteRecent discovery and development of inhibitors targeting coronaviruses

Review
Keynote
Recent discovery and development of inhibitors targeting coronaviruses